科兴制药：GB08注射液II期临床试验完成首例受试者入组

Core Viewpoint - The announcement highlights the successful completion of the first subject enrollment and administration in the Phase II clinical trial of "GB08 Injection," developed by the company's wholly-owned subsidiary, Shenzhen Kexing Pharmaceutical Co., Ltd. [1] Group 1 - The clinical trial aims to evaluate the efficacy and safety of GB08 Injection for treating children with growth hormone deficiency [1] - This trial is a multi-center, randomized, open-label, positive-controlled Phase II/III clinical study [1] - The ethical approval for the trial has been obtained recently, and the first subject has been enrolled and administered [1] Group 2 - The trial is not expected to have a significant impact on the company's recent financial status and operating performance [1]